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Abstract
This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the
effects of 3,4–methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study
used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release
of both 5-HT and NE by MDMA or by its metabolite 3,4-methylenedioxyamphetamine from transmitter-loaded human cells
expressing the 5-HT or NE transporter. In humans, duloxetine inhibited the effects of MDMA including elevations in
circulating NE, increases in blood pressure and heart rate, and the subjective drug effects. Duloxetine inhibited the
pharmacodynamic response to MDMA despite an increase in duloxetine-associated elevations in plasma MDMA levels. The
findings confirm the important role of MDMA-induced 5-HT and NE release in the psychotropic effects of MDMA. Duloxetine
may be useful in the treatment of psychostimulant dependence.
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Introduction
Amphetamine derivatives, including 3,4-methylenedioxy-
methamphetamine (MDMA, ‘‘ecstasy’’) bind to monoamine
transporters and potently release serotonin (5-hydroxytryptamine
[5-HT]), norepinephrine (NE), and dopamine (DA) through the 5-
HT (SERT), NE (NET), and DA (DAT) transporters, respectively
[1,2,3,4]. The pharmacological effect of MDMA can be blocked
by monoamine transporter inhibitors. In vitro, the MDMA-induced
release of NE, DA, or 5-HT from rat brain synaptosomes
preloaded with monoamines is competitively inhibited by the
monoamine transporter inhibitor indatraline [5,6]. In humans,
SERT inhibition reduced the psychotropic response to MDMA
[7,8,9]. NET inhibition also attenuated the acute effects of
MDMA [10] and amphetamine [11] in humans. In contrast,
clonidine, which inhibits the vesicular release of NE, did not
inhibit the effects of MDMA in humans [12]. Thus, the available
evidence indicates that the MDMA-induced transporter-mediated
release of 5-HT and NE appears to be involved in aspects of the
acute subjective and cardiovascular responses to psychostimulants
[2,7,10,11]. However, the response to MDMA in humans was
only moderately affected when either the SERT or NET was
pharmacologically blocked [7,10]. Therefore, we evaluated the
effects of dual SERT and NET inhibition with duloxetine on the
pharmacokinetics (PK) and pharmacodynamics (PD) of MDMA in
humans. Duloxetine was used because it is the most potent and
selective dual SERT and NET inhibitor, although it also inhibits
the DAT with 10- to 100-fold lower potency compared with the
SERT and NET [13,14]. MDMA is mainly metabolized to 3,4-
dihydroxymethamphetamine (HHMA) by cytochrome P450
(CYP) 2D6-mediated O-demethylation, followed by catechol-O-
methyltransferase-catalyzed methylation to 4-hydroxy-3-methox-
ymethamphetamine (HMMA) [15]. Because duloxetine inhibits
CYP 2D6 [16], we expected an increase in plasma MDMA
concentrations after duloxetine pretreatment. MDMA is also N-
demethylated to the active metabolite 3,4-mehthylenedioxyam-
phetamine (MDA). Whether the effects of MDA on 5-HT and NE
release are inhibited by transporter inhibitors is unknown.
Additionally, the inhibition of MDMA’s effect on 5-HT and NE
release by duloxetine has not been studied. Therefore, we also
assessed the effects of duloxetine on 5-HT and NE release induced
by MDMA or MDA in vitro using cells that express the respective
human transporters. We also sought to link the in vitro and in vivo
data to provide additional insights into the differential modulatory
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role of 5-HT and NE in the effects of MDMA in humans. Because
the data on monoamine transporter affinity and inhibition have
mostly been derived from studies that used rat transporters [17],
we investigated the binding and inhibition characteristics of the
human monoamine transporters for MDMA, MDA, and dulox-
etine and the transporter inhibitors used in previous clinical studies
[7,8,9,10] and in vitro studies [5,6]. Finally, we used an ex vivo
binding assay to assess whether plasma samples taken from the
drug-treated participants in the clinical study exhibit SERT, NET,
and DAT-binding properties ex vivo.
The overall hypothesis of the present study was that duloxetine
would potently bind to SERT and NET and block theMDMA- and
MDA-induced transporter-mediated release of 5-HT and NE in vitro
and markedly reduce the acute effects of MDMA in vivo in humans.
Methods
Clinical Study
The protocol for the clinical trial, the CONSORT checklist,
and the CONSORT flowchart are available as supporting
information; see Protocol S1, Checklist S1, and Figure 1. There
were no changes to the protocol during the study.
Ethics
The study was conducted in accordance with the Declaration of
Helsinki and approved by the Ethics Committee of the Canton of
Basel, Switzerland. All of the subjects provided written informed
consent before participating in the study, and they were paid for
their participation.
Design
We used a double-blind, placebo-controlled, randomized,
crossover design with four experiential conditions (placebo-placebo,
duloxetine-placebo, placebo-MDMA, and duloxetine-MDMA) in a
balanced order. The washout periods between the sessions were at
least 10 days long.
Participants
Sixteen healthy subjects (eight men, eight women) with a
mean6SD age of 26.166.0 years participated in the study. The
allocation to treatment order was performed by drawing from
blocks of eight different balanced drug treatment sequences by a
pharmacist not involved in the study. Each code was stored in a
sealed envelope until the termination of the study. Data from all 16
subjects were available for the final analysis (Figure 1). The
sample-size estimation showed that 13 subjects would be needed to
detect a meaningful reduction of 20% of the MDMA drug effect
by duloxetine with more than 80% power using a within-subjects
study design. The exclusion criteria included the following; (i) age
,18 or.45 years, (ii) pregnancy determined by a urine test before
each session, (iii) body mass index ,18.5 kg/m2 or .25 kg/m2,
(iv) personal or family (first-degree relative) history of psychiatric
disorder (determined by the structured clinical interview of Axis I
and Axis II disorders according the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition [18] supplemented by the SCL-90-R
Symptom Checklist [19,20] (v) regular use of medications, (vi)
chronic or acute physical illness assessed by physical examination,
electrocardiogram, standard hematological, and chemical blood
analyses, (vii) smoking more than 10 cigarettes per day, (viii) a
lifetime history of using illicit drugs more than five times with the
exception of cannabis, (ix) illicit drug use within the last 2 months,
and (x) illicit drug use during the study determined by urine tests
conducted before the test sessions. None of the 16 subjects had
used ecstasy previously. The subjects were asked to abstain from
excessive alcohol consumption between the test sessions and limit
their alcohol use to one glass on the day before the test session. All
of the subjects were phenotyped for cytochrome P450 (CYP) 2D6
Figure 1. CONSORT flowchart.
doi:10.1371/journal.pone.0036476.g001
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activity using dextromethorphan. Thirteen extensive, two inter-
mediate, and one poor CYP 2D6 metabolizer were identified in
the study. The female subjects were investigated during the
follicular phase (day 2–14) of their menstrual cycle.
Drugs
(6 )MDMA hydrochloride (C11H15NO2, Lipomed, Arlesheim,
Switzerland) was obtained from the Swiss Federal Office of Public
Health and prepared as gelatin capsules (100 mg and 25 mg).
Identical placebo (lactose) capsules were prepared. MDMA was
administered in a single absolute dose of 125 mg that
corresponded to an average dose of 1.8760.36 mg/kg body
weight. This dose of MDMA corresponds to a typical recreational
dose of ecstasy, and comparable doses of MDMA have previously
been used in controlled settings. Duloxetine (Cymbalta, Eli Lilly,
Vernier, Switzerland) was prepared as 60 mg gelatine capsules,
and identically looking placebo (lactose) capsules were similarly
prepared. Duloxetine (120 mg) or placebo was administered twice
16 and 4 h before MDMA or placebo administration, respectively.
The dose of the two administrations of duloxetine (120 mg/day on
two separate days) was in the upper range of the chronic doses
used clinically (60–120 mg/day). This dosing schedule was used to
obtain high plasma concentrations of duloxetine similar to those
reached with chronic administration of 60 mg/day. Drugs were
administered without food.
Assessments
Psychometric measures. The psychometric measures in-
cluded Visual Analog Scales (VAS) [8,10], the Adjective Mood
Rating Scale (AMRS) [21], and 5-Dimensions of Altered States of
Consciousness (5D-ASC) [22,23]. The VASs included ‘‘any drug
effect,’’ ‘‘good drug effect,’’ ‘‘bad drug effect,’’ ‘‘drug liking,’’
‘‘drug high,’’ ‘‘stimulated,’’ ‘‘fear,’’ ‘‘closeness to others,’’ ‘‘talka-
tive,’’ and ‘‘open’’ [8,10,12,24,25]. The VASs were pre-
sented as 100 mm horizontal lines marked ‘‘not at all’’ on the
left and ‘‘extremely’’ on the right. The VASs for ‘‘closeness to
others,’’ ‘‘open,’’ and ‘‘talkative’’ were bidirectional (650 mm).
The VASs were administered 4 h before and 0, 0.33, 1, 1.5, 2, 2.5,
3, 3.5, 4, and 5 h after MDMA or placebo administration. The 60-
item Likert-type scale of the short version of the AMRS [21] was
administered 4 h before and 1.25, 2, and 5 h after MDMA or
placebo administration. The AMRS contains subscales for activity,
extroversion and introversion, well-being, emotional excitation,
anxiety-depression, and dreaminess. The 5D-ASC rating scale
measures alterations in mood, perception, experience of self in
relation to the environment, and thought disorder. The 5D-ASC
rating scale comprises five subscales or dimensions [22] and 11
lower-order scales [23]. The 5D-ASC dimension ‘‘oceanic
boundlessness’’ (OB, 27 items) measures derealization and
depersonalization associated with positive emotional states, rang-
ing from heightened mood to euphoric exaltation. The corre-
sponding lower-order scales include ‘‘experience of unity,’’
‘‘spiritual experience,’’ ‘‘blissful state,’’ and ‘‘insightfulness.’’ The
5D-ASC dimension ‘‘anxious ego dissolution’’ (AED, 21 items)
summarizes ego disintegration and loss of self-control phenomena,
two phenomena associated with anxiety. The corresponding
lower-order scales include ‘‘disembodiment,’’ ‘‘impaired control
of cognition,’’ and ‘‘anxiety.’’ The dimension ‘‘visionary restruc-
turalization’’ (VR, 18 items) consists of the lower-order scales
‘‘complex imagery,’’ ‘‘elementary imagery,’’ ‘‘audiovisual synes-
thesia,’’ and ‘‘changed meaning of percepts.’’ Two other
dimensions of the scale were not used in our study. The global
ASC score was determined by adding the OB, AED, and VR
scores. The 5D-ASC scale was administered 4 h after MDMA or
placebo administration.
Physiologic measures. Physiologic measures were assessed
repeatedly 4, 3, 2, and 1 h before and 0, 0.33, 0.66, 1, 1.5, 2, 2.5,
3, 4, 5, and 6 h after MDMA or placebo administration. Heart
rate, systolic blood pressure, and diastolic blood pressure were
measured using an OMRON M7 blood pressure monitor
(OMRON Healthcare Europe, Hoofddorp, The Netherlands).
Measures were taken twice per time point with an interval of
1 min, and the average was used for the analysis. Core (tympanic)
temperature was assessed using a GENIUS 2 ear thermometer
(Tyco Healthcare Group, Watertown, NY). The temperature of
the room was maintained at 23.260.5uC. Adverse effects were
assessed using the List of Complaints (LC) [26], which consists of
66 items that yield a total adverse effects score and reliably
measure physical and general discomfort.
Plasma catecholamines and Pharmacokinetics (PK).
Blood samples to determine the concentrations of NE and
epinephrine were collected 4 h before and 1 and 2 h after
MDMA or placebo administration. The levels of free cate-
cholamines (NE and epinephrine) were determined using high-
performance liquid chromatography (HPLC) with an elec-
trochemical detector as described previously [10]. Plasma
concentrations of copeptin were also determined in this study as
reported elsewhere [27]. Samples of whole blood for the
determination of MDMA, MDA, HMMA, and duloxetine were
collected into lithium heparin monovettes -4, 0, 0.33, 0.66, 1, 1.5,
2, 2.5, 3, 4, and 6 h after administration of MDMA or placebo.
Plasma concentrations of MDMA, MDA, HMMA, and duloxetine
were analyzed by HPLC coupled to a tandem mass spectrometer
as described previously [12]. The assays were linear in the
concentration ranges of 1–1000 ng/ml for MDMA and MDA, 1–
500 ng/ml for HMMA, and 2.5–1000 ng/ml for duloxetine. The
performance of the method was monitored using quality control
(QC) samples at the lower limit of quantification (LLOQ) and at
two or three QC concentrations. The interassay accuracy values
for the QC samples ranged from 97.5% to 100% for MDMA,
from 95.3% to 103% for MDA, from 91.1% to 106% for HMMA,
and from 93.2% to 96.4% for duloxetine. The interassay precision
values ranged from 2.8% to 8.0% for MDMA, from 3.8% to
10.5% for MDA, from 3.1% to 8.8% for HMMA, and from 4.7%
to 9.3% for duloxetine. No hydrolysis was performed. Thus, the
values for HMMA represent the drug concentrations of the non-
conjugated metabolite. All blood samples were collected on ice
and centrifuged within 10 min at 4uC. The plasma was then stored
at –20uC until the analysis.
In vitro Studies
Binding to monoamine transporters in vitro. Human
embryonic kidney (HEK) 293 cells (Invitrogen, Zug, Switzerland)
stably transfected with the human NET, SERT, or DAT as
previously described [28] were cultured. The cells were collected
and washed three times with phosphate-buffered saline (PBS). The
pellets were frozen at –80uC. The pellets were then resuspended in
400 ml of 20 mMHEPES-NaOH, pH 7.4, that contained 10 mM
EDTA at 4uC. After homogenization with a Polytron (Kinematica,
Lucerne, Switzerland) at 10000 rotations per minute (rpm) for
15 s, the homogenates were centrifuged at 480006g for 30 min at
4uC. Aliquots of the membrane stocks were frozen at –80uC. All
assays were performed at least three times. The test compounds
were diluted in 20 ml of binding buffer (252 mM NaCl, 5.4 mM
KCl, 20 mM Na2HPO4, 3.52 mM KH2PO4, pH 7.4) and 10
point dilution curves were made and transferred to 96-well white
polystyrene assay plates (Sigma-Aldrich, Buchs, Switzerland). N-
Duloxetine and MDMA
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methyl-3H-nisoxetine (,87 Ci/mmol, Perkin-Elmer) was the
radioligand for the NET assay and had a dissociation constant
(Kd) of 9 nM. Fifty microliters of 12 nM [
3H]-nisoxetine was
added to each well of the assay plates, targeting a final [3H]-
nisoxetine concentration of 3 nM. [3H]-citalopram (,72 Ci/
mmol; Perkin-Elmer) was the radioligand for the SERT assay
and had a Kd of 2.2 nM. Fifty microliters of 8 nM [
3H]-
citalopram was added to each well of the SERT assay plates,
targeting a final [3H]-citalopram concentration of 2 nM. [3H]-
WIN35,428 (,86 Ci/mmol; Perkin-Elmer) was the radioligand
for the DAT assay and had a Kd of 12 nM. Fifty microliters of
[3H]-WIN35,428 (,40 nM concentration) was added to each well
of the hDAT assay plates, targeting a final [3H]-WIN35428
concentration of 10 nM. Twenty microliters of binding buffer
alone in the assay plate defined the total binding, whereas binding
in the presence of 10 mM indatraline defined nonspecific binding.
Frozen NET, SERT, or DAT membrane stocks were thawed and
resuspended to a concentration of approximately 0.04 mg
protein/ml binding buffer (1:1 diluted in H2O) using a polytron
tissue homogenizer. The membrane homogenates (40 mg/ml)
were then lightly mixed for 5–30 min with polyvinyl toluene (PCT)
wheat germ agglutinin-coated scintillation proximity assay (WGA-
SPA; Amersham Biosciences) beads at 7.7 mg beads/ml homog-
enate. One hundred thirty microliters of the membrane/bead
mixture were added to each well of the assay plate that contained
radioligand and test compounds (final volume in each well, 200 ml)
to start the assay, which was incubated for approximately 2 h at
room temperature with agitation. The assay plates were then
counted in the PVT SPA counting mode of a Packard Topcount.
Fifty microliters of the [3H]-nisoxetine, [3H]-citalopram, or [3H]-
WIN35428 stocks were counted in 5 ml of ReadySafe scintillation
cocktail (Beckman Industries) on a Packard 1900CA liquid
scintillation counter to determine the total counts added to the
respective assays. Non-linear regression was used to fit the data to
sigmoid curves and determine IC50 values for binding and uptake.
Ki values for binding and uptake were calculated using the
following Cheng-Prusoff equation: Ki = IC50/(1+ [S]/Km).[29].
Monoamine uptake in vitro. Two different methodological
approaches were used to assess the effects of the drug on
monoamine uptake. Method A used centrifugation through silicon
oil, and method B used buffer to stop the reaction and wash the
cells. Method A: The SERT, NET, and DAT functions were
evaluated in human HEK 293 cells that stably expressed human
SERT, NET, and DAT. The cells were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen, Zug, Switzerland) with 10%
fetal bovine serum and 250 mg/ml geneticine. The cells (100 ml,
46106 cells/ml) were incubated for 10 min with 25 ml uptake
buffer (9.99 mM L-glucose, 0.492 mM MgCl2, 4.56 mM KCl,
119.7 mM NaCl, 0.7 mM NaH2PO4, 1.295 mM NaH2PO4,
0.015 mM sodium bicarbonate, and 1 mg/ml ascorbic acid for
[3H]-DA uptake) that contained various concentrations of
inhibitor at 25uC. Fifty microliters of 5 nM (final concentration)
[3H]-5-HT (80 Ci/mmol; Anawa), [
3H]-NE (14.8 Ci/mmol;
Perkin-Elmer), or [3H]-DA (13.8 Ci/mmol; Perkin-Elmer) was
added to start uptake. Uptake was stopped after 10 min, and
radioactivity was measured as described below for 5-HT and NE
release. Cell integrity after MDMA treatment was confirmed by
the Toxilight toxicity assay (Lonza, Basel, Switzerland). The data
were fit by non-linear regression, and Km, EC50, and Emax values
were calculated using Prism (GraphPad, San Diego, CA).
Preliminary experiments showed that the accumulation of 5-HT
and NE by the cells was time-dependent and complete after 5 min
for both 5-HT and NE, respectively. The 5-HT and NE transport
velocity was concentration-dependent and could be described by
Michaelis-Menten kinetics. The Km values were 4896147 nM,
4506125 nM, and 17076297 nM for 5-HT, NE, and DA,
respectively. Nonspecific uptake was determined for each exper-
iment in the presence of 10 mM fluoxetine for SERT cells, 10 mM
nisoxetine for NET cells, and 10 mM mazindol for DAT cells and
subtracted from the total counts to yield specific uptake.
Nonspecific uptake was ,10% of total uptake. Method B: Ligand
potencies to inhibit [3H]-DA, [3H]-5-HT, and [3H]-NE uptake via
the human DAT, SERT and NET recombinantly expressed in
HEK 293 cells were determined. The cells were grown in
Dulbecco’s modified Eagle’s medium (Invitrogen, Zug, Switzer-
land) with 10% fetal bovine serum and 250 mg/ml geneticine in
cell culture flasks. One day before the experiment, the cells were
seeded in a volume of 110 ml at a density of 0.3 million cells/ml in
96-well plates (Packard) and incubated at 37uC and 5% CO2
overnight. On the day of the uptake experiment, the 96-well plates
that contained the cells were washed with Krebs Ringer
bicarbonate buffer (Sigma-Aldrich, Buchs, Switzerland). Test
compounds (100 ml, diluted in Krebs Ringer bicarbonate buffer)
were added to the microtiter plates and incubated at 37uC for
30 min. Afterward, 50 ml [3H]-DA (35–54 Ci/mmol; Perkin-
Elmer; final concentration, 100 nM), [3H]-5-HT (28–100 Ci/
mmol; Perkin-Elmer; final concentration, 10 nM), or [3H]-NE
(5.3–14 Ci/mmol; Perkin-Elmer; final concentration, 100 nM)
were added to DAT-, SERT-, and NET-containing cells,
respectively, and incubated for 10 min at 37uC. Extracellular
[3H]-DA, [3H]-5-HT, and [3H]-NE were removed, and the plates
were washed twice with Krebs Ringer bicarbonate buffer.
Nonspecific uptake was determined in the presence of 10 mM
indatraline. Scintillant (Microscint 40, 250 ml) was dispensed to
every well, and radioactivity was determined at least 1 h later on
the Packard Topcount plate reader. The data were fit by non-
linear regression, and the IC50 was calculated using Excel
(Microsoft, Redmont, CA, USA). The compounds were tested at
least three times. The Km values were 1082 nM for [
3H]-5-HT
and .10000 nM for [3H]-DA and [3H]-NE.
5-HT and NE release in vitro. Transporter-mediated
MDMA- and MDA-induced 5-HT and NE release was evaluated
using [3H]-5-HT- and [3H]-NE-preloaded HEK 293 cells that
stably expressed human SERT and NET, respectively. The
procedures were adapted from previous studies [2,3]. SERT- or
NET-expressing cells (100 ml, 46106 cells/ml) were incubated at
25uC for 10 min with 50 ml of 5 nM (final concentration) [3H]-5-
HT or 10 nM [3H]-NE solutions, respectively. Steady-state load
with radiolabeled substrate was reached within 5 min and
remained stable for 60 min for both cell lines. Duloxetine or
other transporter inhibitors (5 ml) were added after 10 min, and
the release of [3H]-5-HT and [3H]-NE was then initiated after
another 2 min by the addition of MDMA, MDA, or buffer (25 ml).
The release reaction was stopped after 10 and 30 min for [3H]-5-
HT and [3H]-NE, respectively. The release times were based on
the evaluation of the release-over-time curves for MDMA and
MDA. The release of [3H]-5-HT and [3H]-NE was complete
within 5 and 25 min, respectively, when a new steady state was
reached and maintained for 30 min. To stop the release reaction
and wash the cells, 100 ml of the cell suspension was transferred to
0.5 ml microcentrifuge tubes that contained 50 ml of 3 M KOH
and 200 ml silicon oil (1:1 mixture of silicon oil types Ar20 and
Ar200; Wacker Chemie, Munich, Germany) and centrifuged in a
tabletop microfuge (Eppendorf, Basel, Switzerland) for 3 min at
13,200 rpm. This transports the cells through the silicon oil layer
to the KOH layer, thereby separating the cells from the buffer,
which remains on top of the silicon oil layer [30]. The centrifuge
tubes were then transferred to liquid nitrogen. The amount of
Duloxetine and MDMA
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tracer that remained in the cells was quantified by cutting the
frozen centrifuge tube above the KOH/oil interface and putting
the tip of the tube with the cell pellet in a scintillation vial that
contained 500 ml lysis buffer (0.05 M TRIS-HCl, 50 mM NaCl,
5 mM EDTA, and 1% Nonidet P-40 substitute in water). The
samples were then shaken for 1 h on a rotary shaker, and 7 ml of
scintillation fluid (Ultimagold, Perkin Elmer, Schwerzenbach,
Switzerland) was added. Cell-associated radioactivity was then
counted. The silicon oil assay allowed for the precise termination
of the transport/release process and an effective cell wash. The
experimental control condition (100% retained) was defined as the
[3H]-5HT or [3H]-NE that remained in the cells when buffer and
duloxetine were added without MDMA or MDA. A second
control condition (100% release) was defined as the [3H]-5-HT or
[3H]-NE released by 100 mM tyramine [6]. Data analysis using
either of the two control conditions yielded similar results, and the
data are presented as release expressed as the percentage of
monoamine retained. Dose-response curves were generated using
9–11 concentrations of MDMA/MDA. Nonspecific binding/
uptake was determined using preincubation with 10 mM fluoxetine
for SERT cells and 10 mM nisoxetine for NET cells before
incubation with radioligands and was ,3% of total activity. All
data points were derived from at least three independent
experiments, each assayed in triplicate. The data were fit by
non-linear regression, and EC50 and Emax values were calculated
using Prism (GraphPad, San Diego, CA).
Ex vivo Binding to Monoamine Transporters
Plasma samples for assessing ex vivo binding to monoamine
transporters were collected 120 min after MDMA/placebo
administration. We determined the potencies of the plasma to
inhibit [3H]-nisoxetine, [3H]-citalopram, and [3H]-WIN35,428
binding to NET, SERT, and DAT, respectively, according to the
method described previously [10]. IC50 values were calculated as a
percentage of the plasma sample dilutions required to obtain 50%
of the maximum effect. Indatraline (10 mM) in human plasma was
used to achieve 100% inhibition. Undiluted plasma samples were
set at 100%. Thus, an IC50 of 10% indicates that a 10-fold diluted
plasma sample displaced 50% of the radioligand.
Statistical Analyses
Pharmacodynamics. Clinical data values were transformed
to differences from baseline. Peak effects (Emax) were determined
for repeated measures. Emax values were compared using General
Linear Models repeated-measures analysis of variance, with drug
as within-subject factor, using Statistica 6.0 software (StatSoft,
Tulsa, OK). Tukey post hoc comparisons were performed based on
significant main effects of treatment. Additional analyses of
variance were performed, with period as factor to exclude period
effects. Correlation analyses were performed using Pearson’s
correlations. The criterion for significance was p,0.05. Mean
arterial pressure (MAP) was calculated from diastolic blood
pressure and systolic blood pressure using the following formula:
MAP=DBP+(SBP - DBP)/3.
Pharmacokinetics. The plasma concentration data for
MDMA, MDA, HMMA, and duloxetine were analyzed using
non-compartmental methods. Cmax and tmax were obtained
directly from the observed concentration-time curves. The
terminal elimination rate constant (lz) was estimated by log-linear
regression after semilogarithmic transformation of the data, using
the last two to three data points of the terminal linear phase of the
concentration-time curve of MDMA or duloxetine. Terminal
elimination half-life (t1/2) was calculated using lz and the equation
t1/2 = ln2/lz. The area under the plasma concentration-time curve
up to 6 h (AUC0-6h) was calculated using the linear trapezoidal
rule. The AUC0–‘ was determined by extrapolation of AUC0–6h
using lz. The PK parameters were determined using the PK
functions for Excel (Microsoft, Redmont, CA, USA). Plasma
concentrations were only determined up to 6 h after MDMA
administration because the aim of the study was to assess potential
changes in MDMA plasma levels while relevant pharmacody-
namic effects or MDMA were present. It was therefore not
possible to determine t1/2 for HMMA and MDA because of their
long t1/2, which would require sampling for an extended time.
PK-PD modeling: First, a soft-link PK-PD model was used to
evaluate the in vivo relationship between the concentration of
MDMA and subjective effect of the drug. The change in the VAS
for any drug effect was used as the pharmacodynamic measure in
each individual. Because we observed clockwise hysteresis in the
effect-concentration relationship over time, we used PK-PD data
pairs within the ascending part of the individual curves up to Emax
or Cmax. Our estimate of Emax, which should represent the
maximal response portion of the dose-response curve, may already
have been affected by tolerance. However, Emax values of 100%
(scale maximum) or stable high values were reached by most
subjects, indicating that tolerance was not an issue early in the
effect-time curve. Based on the good brain penetration of MDMA
and absence of a time lag, we assumed rapid equilibration between
plasma and the central compartment (brain). A sigmoid Emax
model was then fitted to the pooled data of all individuals: E=Emax
6Cp
h/(EC50
h+Cph), in which E is the observed effect, Cp indicates
the MDMA plasma concentration, EC50 indicates the plasma
concentration at which 50% of the maximal effect is reached, Emax
is the maximal effect, and h is the Hill slope. The sigmoid Emax
model provided a better fit than a simple Emax or linear model.
Data pooling was used because only few data pairs were available
per subject. Non-linear regression was used to obtain parameter
estimates. Second, we also used a hard-link PK-PD model to
predict in vivo PD effects based on the in vitro concentration-
response data linked to the observed individual in vivo PK. The in
vitro concentration-response relationship was described by a
sigmoidal dose-response variable slope model fitted to the effects
of MDMA on 5-HT or NE release using non-linear regression
(Prism, GraphPad, San Diego, CA). The equation was the
following: E=Emax/(1+10(LogEC50-C)6h), in which C denotes the
concentration of MDMA in the assay, and h denotes the Hill slope.
The in vitro effect-concentration relationship was determined for
MDMA-induced 5-HT and NE release separately, and separate
PD predictions were derived for each model. Similar to the soft-
link PK-PD model, a single compartment PK model (plasma=
brain concentration) was used, and only ascending PK or PD
values were included. The in vivo data were linked to the PK of
each individual, and a mean predicted effect-time curve was
established.
Results
Pharmacodynamics (PD)
Duloxetine markedly reduced the psychotropic and cardiosti-
mulant responses to MDMA in humans. Duloxetine decreased all
aspects of MDMA’s subjective effects in the VASs [8,10],
including psychostimulant effects such as feelings of ‘‘good drug
effects,’’ ‘‘drug liking,’’ ‘‘drug high,’’ and ‘‘stimulation’’ (Table 1;
Fig. 2b-d) but also so-called ‘‘entactogenic’’ or ‘‘empathogenic’’
MDMA-typical effects [31,32] such as feelings of being ‘‘open,’’
‘‘closer to others,’’ and more ‘‘talkative’’ (Table 1; Fig. 2e and f). In
the AMRS [21], duloxetine prevented MDMA-induced increases
in ‘‘well-being,’’ ‘‘emotional excitation,’’ and ‘‘extroversion’’
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(Fig. 3). In the 5D-ASC [22,23], duloxetine robustly reduced
MDMA’s effects on the total ASC score (p,0.001) and in all three
main dimensions of the scale (main effect of drug: F3,45 = 26.2,
32.6, 5.67, and 26.6 for ASC, OB, AED, and VR, respectively; all
p,0.001; Fig. 4). Duloxetine prevented the MDMA-induced
increase in circulating plasma NE levels, an endocrine marker for
sympathetic system activation (Table 1), and reduced the blood
pressure and heart rate response to MDMA (Table 1; Fig. 5).
MDMA-induced increases in plasma NE at 60 min correlated
with elevations in MAP (r =0.57, p,0.05) and increases in VAS
scores for ‘‘good drug effects,’’ ‘‘liking,’’ ‘‘open’’ (r = 0.65, 0.69,
0.77 and 0.63, respectively; all p,0.01), supporting the modula-
tory role of NE in these effects of MDMA. ANOVAs with period
as factor showed no effect of treatment order, confirming the
absence of period effects.
Pharmacokinetics
The robust decrease in the PD response to MDMA after
duloxetine was not the result of a pharmacokinetic interaction
between duloxetine and MDMA because duloxetine increased
exposure to MDMA. MDMA and duloxetine are both substrates
and inhibitors of CYP 2D6 [16]. The moderate CYP 2D6
inhibitor duloxetine increased both the Cmax and AUC0-6h of the
CYP 2D6 substrate MDMA by 1664% (mean 6 SEM;
F1,15 = 12.64, p,0.01) and 1865% (F1,15 = 8.95, p,0.01), respec-
tively (Fig. 6 and Table 2). Duloxetine had no effect on exposure to
MDA, the active metabolite of MDMA. Duloxetine decreased the
Cmax and AUC0-6h of the inactive CYP 2D6-formed MDMA
metabolite HMMA by 4666% (F1,15 = 70.03, p,0.001) and
4866% (F1,15 = 166.10, p,.001), respectively. Plasma duloxetine
concentrations nonsignificantly increased beginning 1 h after
Table 1. Pharmacodynamic peak drug effects.
Placebo-
placebo
Duloxetine-
placebo
Placebo-
MDMA
Duloxetine-
MDMA F3,45 = p,
Visual Analog Scales
Any drug effect Emax 3.8163.62 6.0062.52
### 86.6963.57*** 33.1967.74*** ### 74.47 0.001
Good drug effect Emax 4.5664.37 8.7565.01
### 89.3864.67*** 40.5669.50*** ### 42.89 0.001
Drug liking Emax 4.1364.06 7.5664.43
### 90.6964.82*** 38.3868.91*** ### 52.60 0.001
Drug high Emax 1.9461.94 4.8162.93
### 87.8164.85*** 28.9469.35** ### 55.45 0.001
Stimulated Emax 4.1361.94 5.1362.45
### 76.3166.84*** 22.2567.65### 46.25 0.001
Open Emax 1.3860.94 0.3860.38
### 32.1664.29*** 6.0063.26### 36.88 0.001
Closeness Emax 0.0060.00 0.0060.00
### 27.3163.87*** 4.6362.49### 37.32 0.001
Talkative Emax 1.1960.81 0.3160.31
### 28.8165.12*** 10.6963.73### 21.13 0.001
Adjective Mood Rating Scale
Well-being Emax 1.6660.49 0.3860.16
### 7.0661.01*** 3.5661.08## 18.0 0.001
Emotional excitation Emax 0.6960.35 0.6960.27
### 4.9460.97*** 1.3160.37### 14.7 0.001
Extroversion Emax 0.6360.24 0.3860.16
### 3.5060.61*** 1.4460.43### 17.5 0.001
Introversion Emax 0.3861.56 1.1360.30 2.6260.65** 1.6960.59 5.4 0.01
Dreaminess Emax 0.6360.33 1.3560.35 2.9460.66** 1.8160.48 4.1 0.05
Activity Emin 21,8860.50 22.6960.69 24.6961.04* 22.8160.78 2.6 0.06
Circulating catecholamines
Epinephrine (nM) Emax 0.4260.12 0.4660.10 0.5060.12 0.2660.10 ns
Norepinephrine (nM) Emax 20.2260.13 20.1860.07
### 0.4460.12*** 20.1960.10### 14.7 0.001
Physiologic effect
SBP (mm Hg) Emax 8.5661.75 6.1961.42
### 29.9463.41*** 10.9461.58### 24.6 0.001
DPB (mm Hg) Emax 6.2561.25 6.0060.97
### 22.1362.08*** 9.2261.57### 23.3 0.001
MAP (mm Hg) Emax 5.8061.27 5.1161.01
### 21.7662.73*** 8.5461.46### 20.3 0.001
Heart rate (beats/min) Emax 9.1961.29 5.0661.27
### 26.0662.77*** 11.0961.55### 25.5 0.001
Body temperature (uC) Emax 0.2360.04 0.1960.04
### 0.5460.07** 0.3960.08 7.3 0.001
List of Complaints (total score)
Acute adverse effects at 3 h 20.0660.52 21.8161.09### 5.5661.72** 21.2561.49## 29.5 0.001
Sub-acute adverse effects at 24 h 21.0060.58 22.8861.35## 3.8861.09* 20.3861.32# 24.6 0.001
Ex vivo binding (IC50%)
NET .25 14.360.6*** ## 23.460.7 13.760.7*** ### 20.4 0.001
SERT .25 1.560.2 *** ### .25 1.460.2 *** ### 243.1 0.001
DAT .25 .25 .25 .25
Values are mean6SEM of changes from baseline of 16 subjects. *p,.05, **p,.01, and ***p,.001 vs. Placebo-placebo. #p,.05, ##p,.01, ###p,.001 vs. Placebo-
MDMA. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure. IC50%, inhibition constant calculated as % of plasma sample dilution
with undiluted plasma set as 100%; NET, norepinephrine transporter; SERT, SERT, serotonin transporter; DAT, dopamine transporter; ns, nonsignificant.
doi:10.1371/journal.pone.0036476.t001
Duloxetine and MDMA
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36476
Figure 2. Duloxetine inhibited the psychotropic effects of MDMA. MDMA produced stimulant-like (b–d) and ‘‘entactogenic’’ (e, f) effects
compared with placebo (p,0.001 for all scales). Duloxetine significantly inhibited MDMA-induced elevations in all of these subjective effects (a–f)
(p,0.001 for all scales). Values are expressed as mean+SEM (n =16).
doi:10.1371/journal.pone.0036476.g002
Figure 3. Duloxetine prevented the acute emotional effects of MDMA in the Adjective Mood Rating Scale. MDMA produced a state of
well-being (a), emotional excitation (b), increased introversion at drug onset at 1.25 h (d), increased extroversion at 2 h (c), increased dreaminess (e),
and decreased performance-oriented activity (f) (*p,0.05, **p,0.01, ***p,0.001, vs. placebo-placebo). Duloxetine prevented MDMA-induced
elevations in well-being, emotional excitation, and extroversion (a-c) (###p,0.001, placebo-MDMA vs. duloxetine-MDMA). Values are expressed as
mean+SEM (n =16).
doi:10.1371/journal.pone.0036476.g003
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MDMA administration (Fig. 5), consistent with the inhibitory
effect of MDMA on duloxetine metabolism via CYP 2D6.
Interindividual differences in CYP 2D6 activity also affected the
PK of MDMA. Lower CYP 2D6 function (i.e., a lower
dextromethorphan:dextrorphan urine concentration ratio) was
associated with a longer t1/2 of MDMA (r =0.65, p,0.01).
PK-PD Relationship
Fig. 7 shows the mean PD effects of MDMA plotted against
simultaneous plasma concentrations at the different time points
(hysteresis loops). The increases in ‘‘any drug effect’’ (Fig. 7a) and
MAP (Fig. 7b) returned to baseline within 6 h when MDMA
concentrations were still high. This clockwise hysteresis indicates
that a smaller MDMA effect was seen at a given plasma
concentration later in time, indicating rapid acute pharmacody-
namic tolerance, which was similarly described for cocaine [33].
Duloxetine robustly reduced the physical and subjective response
to MDMA, but it increased exposure to MDMA, illustrated by the
downward and rightward shift of the MDMA hysteresis loops
(Fig. 7).
Adverse Effects
MDMA produced adverse effects, such as sweating, difficulty
concentrating, thirst, and lack of appetite, resulting in an increase
in total LC scores at both 3 and 24 h after drug administration
(Table 1). Duloxetine produced daytime somnolence and moder-
ate insomnia. No severe adverse events were observed.
In vitro Studies
MDMA-induced 5-HT and NE release studies in vitro. MDMA
was nonsignificantly more potent in releasing NE via NET than 5-
HT via SERT (IC50 = 0.55 and 1.69 mM, respectively; Fig. 8;
Table 3), consistent with earlier work that used human [3,34] and
rat [2] transporters. MDA similarly released monoamines with
EC50 values of 0.85 and 2.77 mM for NE and 5-HT, respectively
(Fig. 8; Table 3). Thus, both amphetamines were active
transporter-mediated monoamine releasers and exhibited slightly
higher potency at NET than SERT. Duloxetine potently inhibited
the ability of MDMA and MDA to induce 5-HT release from
SERT and NE release from NET cells (Fig. 8). Duloxetine
(0.1 mM) decreased the Emax by approximately 50% and shifted
the concentration-effect curves to the right, consistent with a
mixed competitive and noncompetitive mode of inhibition. A high
concentration of duloxetine (10 mM) completely blocked the effects
of MDMA and MDA (Fig. 8). We then compared the inhibitory
effect of duloxetine on MDMA-induced monoamine release to the
inhibitory effects of the selective SERT inhibitor citalopram and
selective NET inhibitor reboxetine, each of which have been
shown to attenuate some of the effects of MDMA in humans
[7,10]. The potencies of duloxetine and citalopram to inhibit
MDA- and MDMA-induced 5-HT release were similar (Fig. S1;
Table 3). The potencies of duloxetine and reboxetine to block
MDMA-induced NE release were also similar (Fig. S1; Table 3).
These in vitro data indicate that duloxetine inhibited both SERT
and NET similarly to citalopram and reboxetine, respectively.
PK-PD and in vitro-in vivo relationship. Duloxetine
mainly affected the Emax of MDMA in the in vivo PK-PD
relationship of MDMA (Fig. 9a) consistent with a primarily
Figure 4. Duloxetine prevented the acute effects of MDMA in the Altered States of Consciousness (ASC) scale. MDMA significantly
increased the ASC sum score, Oceanic Boundlessness (OB), Anxious Ego Dissolution (AED), and Visionary Restructuralization (VR) dimensions, and
most of the subscales (*p,0.05, **p,0.01, ***p,0.001, placebo-placebo vs. placebo-MDMA). Duloxetine significantly reduced the effect of MDMA in
all dimensions and subscales (#p,0.05, ##p,0.01, ###p,0.001, placebo-MDMA vs. duloxetine-MDMA). Values are expressed as mean+SEM
(n = 16).
doi:10.1371/journal.pone.0036476.g004
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noncompetitive mode of inhibition and similar to the effect of
duloxetine on monoamine release produced by MDMA in vitro.
Duloxetine decreased the Emax from 93.867.3% to 20.864% for
placebo-MDMA compared with duloxetine-MDMA, respectively.
The EC50 values were 92.567.6 ng/mL (0.48 mM) and
83.8625 ng/mL (0.43 mM) for placebo-MDMA and duloxetine-
MDMA, respectively. The EC50 of the PK-PD curve of placebo-
MDMA in humans was 74 ng/ml (0.38 mM), similar to the EC50
values of MDMA to release 5-HT and NE in vitro. The plasma
concentrations of duloxetine (Cmax =112 ng/ml or 0.38 mM) were
also in the range of the concentrations that reduced MDMA-induced
5-HT and NE release in vitro. To relate our in vitro data to the PD of
MDMA in humans, we linked the concentration-effect relationship of
the in vitro effect of MDMA on 5-HT and NE release to the individual
concentration-time curves of our subjects (Fig. 9b). The observed
effect-time curve for MDMA in humans was predicted well by the in
vitro NE release model, assuming similar concentrations in plasma
and brain and no time lag. The 5-HT release model fitted, but 2- to
10-fold higher MDMA concentrations in the brain than in plasma
would be needed to obtain similar pharmacodynamic effects as NE.
The higher potency of MDMA to release NE vs. 5-HT in vitro also
predicted that NE release occurred at lower MDMA plasma and
brain concentrations and therefore sooner after MDMA administra-
tion, playing a predominant role during the initial drug effect (i.e.,
rush, stimulant effect). 5-HT release becomes relatively more
important later in time and predominantly mediates ‘‘entactogenic’’
effects, including feelings of being open and closer to others, that
prevail later. The model predicted that the half-maximal effects
would be reached at 4062 min and 70614 min for NE and 5-HT
release, respectively (Fig. 9b). The observed half-maximal subjective
drug effect of MDMA was reached 4464 min after drug adminis-
tration. At that time, the models predicted 4 (3–6)-fold higher NE
release compared with 5-HT release, consistent with the view of a
primary role for NE in the early effects of MDMA.
Monoamine transporter binding in vitro. The binding of
MDMA and MDA to monoamine transporters was weak (Table 4)
compared with the high potency of MDMA to release 5-HT and
NE. The binding profile of MDMA was consistent with other
binding studies that used human transporters [3] but different
from studies that used rat transporters [17]. Duloxetine showed
more than 100-fold higher affinity for both SERT and NET
compared with the affinity of MDMA for these transporters in the
same assay, supporting our approach of using duloxetine to
prevent MDMA from interacting with SERT and NET (Table 4).
Monoamine uptake inhibition in vitro. MDMA inhibited
NET three-fold more potently than SERT, consistent with previous
studies that used human transporters [3,35] but in contrast to data
derived frommouse and rat transporters [17,35,36] (Table 5). MDA
was equally potent to MDMA in inhibiting NET and SERT. Both
MDMA andMDA showed low potency to inhibit DAT. Duloxetine
was more potent in inhibiting SERT than NET (Table 5), which
was expected [13]. Because the selective SERT inhibitor citalopram
and selective NET inhibitor reboxetine have previously been shown
to attenuate the psychological effects of MDMA [7,10], we
compared duloxetine with these inhibitors. Duloxetine exhibited
similar potency as citalopram to inhibit SERT but 2- to 5-fold lower
potency as reboxetine to inhibit NET (Table 5).
Ex vivo Binding Studies
The ability of duloxetine to block monoamine transporters in
our study was confirmed with an ex vivo assay, in which plasma
from duloxetine-treated subjects inhibited ex vivo radioligand
binding to SERT and NET but not DAT (Table 1). We also
found a 10-fold higher affinity for SERT compared with NET,
Figure 5. Duloxetine reduced the cardiostimulant response to
MDMA. Duloxetine reduced the elevations in mean arterial blood
pressure (a) and heart rate (b) in response to MDMA. Duloxetine also
nonsignificantly lowered the MDMA-induced increase in body temper-
ature (c). Values are expressed as mean+SEM of 16 subjects.
doi:10.1371/journal.pone.0036476.g005
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Figure 6. Duloxetine increased MDMA exposure. Pharmacokinetics of MDMA, MDA, HMMA, and duloxetine (a–d). Duloxetine was administered 16 h
and 4 h before MDMA, which was administered at the 0 h time point. Duloxetine increased the Cmax and AUC0–6 of MDMA (a), had no significant effect on
MDA exposure (b), and decreased the Cmax and AUC0–6 of HMMA (c). Plasma duloxetine concentrations were similar in the duloxetine-placebo and duloxetine-
MDMA groups before MDMA administration (at –4 h and 0 h). Duloxetine concentrations increased 1 h after MDMA administration in the duloxetine-MDMA
vs. duloxetine-placebo group (d). Values are expressed as mean6SEM of 16 subjects. MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-
methylenedioxyamphetamine; HMMA, 4-hydroxy-3-methoxymethamphetamine.
doi:10.1371/journal.pone.0036476.g006
Table 2. Pharmacokinetic parameters of MDMA, MDA, HMMA, and duloxetine.
Cmax (ng/ml) Tmax (h) T1/2 (h) AUC0-6 (ng/ml h) AUC(0-‘) (ng/ml h)
MDMA
Placebo-MDMA 221.31611.63 2.3460.19 8.1760.74 952.75645.89 2908.556275.64
Duloxetine-MDMA 253.63613.60** 2.6660.29 7.1460.40 1106.87657.22** 2915.286154.27
MDA
Placebo-MDMA 11.7560.70 5.5060.22 – 46.6063.02 –
Duloxetine-MDMA 10.6760.72 5.2560.30 – 41.9563.38 –
HMMA
Placebo-MDMA 3.3660.34 1.8460.17 – 13.5761.58 –
Duloxetine-MDMA 2.0060.38*** 1.8960.25 – 8.1461.45*** –
Duloxetine
Duloxetine-placebo 106.77610.25 5.1460.29 10.9761.04 799.88674.40 1960.186229.54
Duloxetine-MDMA 111.6967.06 5.9560.39 11.3761.43 814.31652.73 2189.456297.99
Cmax, maximum plasma concentration; Tmax, time from drug administration to maximum plasma concentration; AUC0-‘, area under concentration-time curve
extrapolated to infinity. HMMA, 4-hydroxy-3-methoxymethamphetamine; MDMA, 3,4-methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine.
**p,.01, ***p,.001, vs. Placebo-MDMA. Values are mean6SEM (n = 16).
doi:10.1371/journal.pone.0036476.t002
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which was previously shown [13] and consistent with the in vitro
profile of duloxetine. We calculated the duloxetine concentration
in the plasma samples using the Ki values of duloxetine for SERT
and NET binding (Table 2) and the IC50 values derived from the
ex vivo binding in the duloxetine-placebo group (Table 1). The
values (mean 6 SE) obtained were 388636 nM and 576644 nM
duloxetine using SERT and NET binding, respectively, which was
well in agreement with the duloxetine plasma concentrations
determined by LC-MS/MS (31462.5 nM). Plasma from MDMA-
treated subjects did not differ from placebo-treated subjects with
regard to ex vivo radioligand binding to monoamine transporters
(Table 1). This finding is consistent with the relatively low in vitro
binding affinity of MDMA, which does not reflect the high
pharmacological activity of the drug. Our assay assessed binding to
Figure 7. Pharmacokinetic-pharmacodynamic (PK-PD) relationship. MDMA effects are plotted against simultaneous MDMA plasma
concentrations (a, b). The time of sampling is noted next to each point in minutes or hours after MDMA administration. The clockwise hysteresis
indicates acute tolerance to the effects of MDMA. Duloxetine pretreatment markedly reduced physical and subjective responses to MDMA in the
hysteresis loops (a, b).
doi:10.1371/journal.pone.0036476.g007
Figure 8. Duloxetine blocked MDMA- and MDA-induced 5-HT and NE efflux. Duloxetine inhibited SERT-mediated 5-HT release by MDMA
(a) and MDA (b). Duloxetine also inhibited NET-mediated NE release by MDMA (c) and MDA (d). Values are expressed as mean 6 SEM (n = 3–6) of
retained radiolabeled substrate following incubation with various concentrations of MDMA and MDA.
doi:10.1371/journal.pone.0036476.g008
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the SERT and NET binding site for [3H]-citalopram and [3H]-
nisoxetine, respectively. A possible explanation for the low affinity
of MDMA in this assay could be a binding site for MDMA that is
different from citalopram and nisoxetine at SERT and NET,
respectively, consistent with the noncompetitive mode of inhibition
of the MDMA-induced 5-HT and NE release by duloxetine.
Discussion
The present study showed that the dual SERT and NET
inhibitor duloxetine markedly decreased the psychotropic and
cardiovascular responses to MDMA in human subjects, confirm-
ing and extending previous work with selective SERT [7,8,9] and
NET [10] inhibitors. The inhibition of the effect of MDMA by
duloxetine in humans was pronounced and primarily noncompet-
itive. In vitro, duloxetine similarly blocked the interactive effects of
MDMA with SERT and NET to release 5-HT and NE. The
present findings provide further support for a central role of SERT
and NET as targets of MDMA with regard to its acute effects in
humans. Previous clinical data indicated that 5-HT release
primarily mediates the MDMA-typical ‘‘empathogenic’’ mood
effects of MDMA [7], whereas NE release may be responsible for
the stimulant and cardiovascular effects of the drug [10]. In the
present study, dual inhibition of 5-HT and NE release robustly
blocked both aspects of the MDMA effect, consistent with the role
of both 5-HT and NE. The precise mode of interaction of
amphetamine derivatives, including MDMA, with monoamine
transporters remains to be elucidated and may involve the
exchange of amphetamine with the transmitter, channel-like
conformational changes of the transporter [37], or transporter
internalization [38,39,40], MDMA is structurally similar to 5-HT,
and a common binding site has been proposed in transmembrane
domain 6 of SERT [41]. A distinct binding site was found for
SERT inhibitors, including citalopram and fluoxetine, proximal to
the 5-HT binding site [42]. Some SERT inhibitors may therefore
allosterically inhibit the interaction between MDMA and SERT to
release 5-HT. Consistent with these molecular data, our study
showed that duloxetine inhibited MDMA-induced 5-HT release,
NE release, and the response to MDMA in humans possibly
according to a noncompetitive inhibition mode. Both our in vitro
and in vivo findings may indicate acute allosteric inhibition of the
effects of MDMA by duloxetine. Prior work with rat brain
synaptosomes showed that indatraline competitively inhibited
MDMA-induced 5-HT release [5]. However, later studies
indicated that many SERT inhibitors also decreased the Emax
for different monoamine releasers, suggesting unique transporter
Table 3. Inhibition of MDMA-induced 5-HT or NE release by different inhibitors.
SERT NET
EC50 (mM) (95% CI)
Emax, % retained,
(95% CI) EC50 (mM) (95% CI)
Emax, % retained,
(95% CI)
MDMA alone 1.69 (1.07–2.66) 48 (42–55) 0.55 (0.17–1.81) 78 (73–82)
MDMA plus 0.1 mM duloxetine 3.51 (0.46–27) 82 (75–90) 0.59 (0.02–19) 90 (84–97)
MDMA plus 0.1 mM citalopram 3.17 (1.89–5.31) 72 (68–77) na na
MDMA plus 0.1 mM reboxetine na Na 3.35 (0.63–179) 78 (56–102)
MDA alone 2.77 (1.78–4.30) 48 (41–54) 0.85 (0.29–2.55) 73 (67–79)
MDA plus 0.1 mM duloxetine 6.86 (0.5–100) 83 (77–89) 2.06 (0.35–12.12) 80 (73–87)
MDA plus 0.1 mM citalopram 5.0 (1.28–19.6) 59 (44–75) na na
95% CI, 95% confidence interval; na, not assessed.
doi:10.1371/journal.pone.0036476.t003
Figure 9. Pharmacokinetic-pharmacodynamic modeling. Duloxetine lowered Emax in the MDMA concentration-effect curve (a) with little
effect on EC50, similar to the effect of MDMA on monoamine release in vitro. Diamonds and circles represent concentration-effect data pairs for
ascending concentrations for placebo-MDMA and duloxetine-MDMA, respectively (a). The solid lines show the fit of a sigmoid Emax PD model to the
observed PK data (a). Dashed lines indicate the 95% confidence interval (CI) of the estimation error (a). NE release predicted the observed subjective
effect of MDMA in vivo (b). Predicted effects are shown as curves (mean695% CI) that represent the fit of the in vitro concentration-effect data to the
16 individual plasma concentration-time curves (b). Observed values are expressed as mean6SEM of 16 subjects (b). MDMA, 3,4-
methylenedioxymethamphetamine; NE, norepinephrine; 5-HT, serotonin.
doi:10.1371/journal.pone.0036476.g009
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interactions for different inhibitor-releaser combinations [6]. This
indicates that different SERT inhibitors may also more or less
effectively reduce the effects of psychostimulants in humans.
Nevertheless, several of the present findings indicate that the effect
of duloxetine on the MDMA response was likely attributable to the
dual inhibition of SERT and NET and not only the result of
potent SERT inhibition alone. First, duloxetine blocked MDMA-
induced NE release in vitro and MDMA-induced increases in
plasma NE in vivo, similar to the selective NET inhibitor reboxetine
[10]. Second, we documented, ex vivo, NET binding in plasma
from duloxetine-treated subjects, and duloxetine has previously
been shown to effectively inhibit NET in humans [13]. Third,
potent and selective inhibition of SERT alone using citalopram in
a single high dose [7], fluoxetine for 5 days [8], or paroxetine for
3 days [9] failed to block the effects of MDMA in humans to the
extent seen here with dual SERT and NET inhibition. Conversely,
selectively blocking NET alone also did not as effectively reduce
the effects of MDMA in humans [10] as blocking both SERT and
NET. The importance of NE as a modulator of the acute effects of
MDMA is also supported by the fact that NE plasma levels after
MDMA treatment in the present study correlated with the
subjective effects and increases in blood pressure. Furthermore, we
compared our in vitro 5-HT and NE release data to clinical data in
humans and showed that the NE release link model better
predicted the ascending subjective effects of MDMA in humans
than the 5-HT release link model. A full assessment of the relative
efficacy of SERT and NET inhibitors to prevent the effects of
MDMA would require administration of SERT and NET
inhibitors alone and in combination and dose-response studies.
However, such studies were not ethically feasible because we did
not want to expose our MDMA-naive subjects to more than two
doses of MDMA in a crossover design.
The role of DA in the reinforcing effects of psychostimulants is
well established, but unknown is whether DA is critical for the
acute effects of MDMA. We found that MDMA exhibited higher
affinity for DAT than NET or SERT in vitro. However, MDMA
functionally exhibited significantly higher inhibition potency of the
SERT and NET compared with DAT, respectively. MDMA is
also more potent in releasing 5-HT and NE compared with DA in
vitro [3], and the magnitude of 5-HT release exceeded DA release
in the nucleus accumbens, striatum, and prefrontal cortex, assessed
with in vivo microdialysis in rats [43]. DAT inhibition did not affect
the acute response to MDMA in rhesus monkeys [44]. Addition-
ally, the D2 dopamine receptor antagonist haloperidol only weakly
attenuated MDMA-induced euphoria in humans and only at doses
that produced significant dysphoria [45]. Whether DAT (NET)
inhibitors, such as bupropion or methylphenidate, inhibit the
effects of MDMA in humans remains to be tested. Duloxetine is a
potent SERT and NET inhibitor but also weak DAT inhibitor
[13,46], which was confirmed in the present in vitro study. We
cannot exclude the possibility that the relatively high dose of
duloxetine used in the present study also inhibited MDMA-
induced DA release. Notably, the present ex vivo binding studies
further showed that the plasma from the subjects treated with
duloxetine exhibited binding to SERT and NET but not DAT.
The transporter-independent vesicular release of monoamines
could theoretically contribute to the mechanism of action of
MDMA. We recently showed that this is not the case for NE
because clonidine, which blocks transporter-independent vesicular
NE release, did not alter the effects of MDMA in humans [12].
Additionally, MDMA did not directly stimulate the Ca2+-
dependent vesicular release of DA [47]. Nevertheless, MDMA
may indirectly stimulate the DA system and induce the vesicular
release of DA by downstream 5-HT-DA or NE-DA system
interactions. For example, 5-HT release by MDMA stimulates DA
release via 5-HT2 receptor activation [48], and this indirect effect
on the DA system is also prevented by SERT inhibition [49].
Thus, downstream DA system activation may be a contributing
factor to MDMA-induced euphoria and the mechanism of action
of psychostimulants in general, even when SERT and NET may
be considered the primary pharmacological targets.
Finally, it is also possible that duloxetine induced adaptive
effects on monoamine systems that reduced the response to
MDMA in vivo. For example, decreases in SERT but not in NET
Table 4. Binding affinities to human monoamine
transporters.
SERT NET DAT
MDMA 13.360.47 22.4614.6 6.5262.24
MDA 18.762.76 17.864.06 26.464.24
Duloxetine 0.00560.002 0.0760.05 0.7060.07
Reboxetine 0.2460.02 0.01560.01 16.264.91
Citalopram 0.00560.001 5.0663.00 21.4610.5
Indatraline 0.0260.008 0.0360.02 0.0160.01
Paroxetine 0.00460.001 0.4260.17 0.7760.18
Values are mean6SD of Ki (mM) (n$3). Radioligands were
3[H]citalopram,
3[H]nisoxetine, and 3[H]-WIN35,428 for SERT, NET, and DAT, respectively.
doi:10.1371/journal.pone.0036476.t004
Table 5. Monoamine transport inhibition.
SERT NET DAT
Ki (mM) (95% CI) Ki (mM) (95% CI) Ki (mM) (95% CI)
MDMA* 1.40 (1.00–1.96) 0.470 (0.334–0.598) 16.7 (11.5–24)
MDA* 2.41 (1.49–3.92) 0.341 (0.253–0.461) 11 (7.5–17)
Duloxetine 0.050 (0.04–0.07)* 0.126 (0.099–0.161)* 2.26 (0.7–3.8)#
Reboxetine 2.07 (1.4–2.6)# 0.036 (0.030–0.044)* 16.4 (11.5–25.2)#
Citalopram* 0.045 (0.037–0.057) .20 .20
Indatraline# 0.09 (0.06–0.12) 0.043 (0.03–0.06) 0.025 (0.01–0.04)
Paroxetine# 0.014 (0.01–0.02) 1.12 (0.03–1.7) 4.83 (2.4–7.3)
*method A; #method B; 95% CI, 95% confidence interval; values are significantly different (p,0.05) if 95% CI do not operlap.
doi:10.1371/journal.pone.0036476.t005
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binding sites were documented following chronic administration of
duloxetine in rats [50].
In conclusion, the present study adds to a better understanding
of the mechanism of action of MDMA in humans. The data
support the roles of both NE and 5-HT in the acute effects of
MDMA. The robust and almost complete prevention of the effects
of MDMA by duloxetine suggests that dual transporter inhibitors
may be useful in the prevention of the acute and long-term
consequences of MDMA and potentially other psychostimulants in
addicted subjects.
Supporting Information
Figure S1 Potency and efficacy of MDMA- and MDA-
induced 5-HT and NE release inhibition by duloxetine,
citalopram, and reboxetine. Both duloxetine and citalopram
inhibited MDMA-induced (a, c) and MDA-induced (b, d) 5-HT
release in vitro with approximately similar potency and efficacy.
The potency of duloxetine to block MDMA-induced NE release
was also similar to the selective NET inhibitor reboxetine (e, f).
EC50 and Emax values are shown in Table 3. Data points represent
mean 6 SEM.
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